Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 5

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 5
---
 vote to approve the Merger Agreement Proposal. This Proxy Statement/Prospectus contains or references detailed information about Enfusion, Clearwater, the Special Meeting, the Merger, the Merger Agreement and the business to be considered by the stockholders of Enfusion at the Special Meeting. Please carefully read this entire Proxy Statement/Prospectus, including the section titled “ Risk Factors” beginning on page 31 of this Proxy Statement/Prospectus for a discussion of the risks relating to the Merger. You also can obtain information about Enfusion from documents that it has filed with the Securities and Exchange Commission.

| Sincerely,                   |
| /s/ Oleg Movchan             |
| Oleg Movchan Chief Executive 
 Officer                      |

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued in connection with the Mergers or determined if this Proxy Statement/Prospectus is truthful or complete. Any representation to the contrary is a criminal offense. This Proxy Statement/Prospectus is dated March 20, 2025 and is first being mailed to stockholders of Enfusion on or about March 20, 2025.

ENFUSION, INC. 125 South Clark Street, Suite 750 Chicago, IL 60603 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON APRIL 17, 2025 This is a notice that a special meeting of stockholders of Enfusion, Inc. (“ Enfusion”) will be held on April 17, 2025, beginning at 9:00 a.m., Central time. The Special Meeting will be a completely virtual, live audio webcast meeting of stockholders and will be held for the following purposes:

| 2. | to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not 
 sufficient votes to approve the Merger Agreement Proposal (the “Adjournment Proposal”).                         |

The accompanying Proxy Statement/Prospectus describes the proposals listed above in more detail. Please refer to the accompanying Proxy Statement/Prospectus, including the Merger Agreement and the other annexes and documents included in, or incorporated by reference into, the accompanying Proxy Statement/Prospectus for further information with respect to the business to be transacted at the Special Meeting. You are encouraged to read the entire Proxy Statement/Prospectus carefully before voting. In particular, see the section titled “Risk Factors.” The board of